Skip to content

Prospective IR-led Sedation Feasibility

Prospective Single-Arm Feasibility Study of IR-led Deep Sedation for Interventional Radiology Procedures Traditionally Performed With Anesthesiology Support

Status
Recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07443254
Enrollment
40
Registered
2026-03-02
Start date
2026-03-02
Completion date
2027-04-03
Last updated
2026-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia, Sedation and Analgesia, Interventional Radiology

Brief summary

This study wants to see if some interventional radiology (IR) procedures can be done without using general anesthesia. General anesthesia needs a lot of staff and equipment. It can also cause side effects. There are not enough anesthesia providers, which makes it harder to use for every procedure. The researchers will test deep sedation with ketamine instead. They will start with 20 patients. If it works well and is safe, they may include up to 40 patients. Patients will be asked to join the study before their procedure. The anesthesia team will be told ahead of time and will be ready to help if needed. The IR team will give the deep sedation and follow all safety rules. The main goal is to finish the procedure without stopping early or switching to general anesthesia. The study will call this successful if fewer than 10% of cases fail. The researchers will also look at patient pain, patient satisfaction, any side effects, and how long recovery takes.

Detailed description

The long-term goal of this study is to improve patient care and healthcare system efficiency by reducing reliance on general anesthesia (GA) for interventional radiology (IR) procedures that have traditionally required anesthesiology support. GA is resource-intensive, associated with airway instrumentation and postoperative side effects, and increasingly constrained by national anesthesiology workforce shortages. This prospective, single-center, single-arm feasibility pilot will evaluate IR-led ketamine-based deep sedation in an initial cohort of 20 patients undergoing IR procedures that would ordinarily be performed under GA, with prespecified expansion to up to 40 participants if early feasibility and safety criteria are met. Eligible patients will be approached prior to their procedure, and the anesthesiology service will be formally consulted in advance and available for immediate escalation if needed. Deep sedation will be administered by the IR sedation team under institutional deep sedation privileges and monitoring standards. The primary outcome is feasibility: successful completion of the planned procedure without failure, where failure is defined as procedure abortion due to inadequate sedation or intolerance, or escalation to anesthesiology takeover and/or conversion to GA. A prespecified feasibility threshold of ≤10% failure will be used. Secondary outcomes include patient-reported pain and satisfaction, peri-procedural adverse events, and recovery duration.

Interventions

DRUGketamine

Ketamine will be administered as follows: initial intravenous bolus of 30-50 mg intravenous ketamine, with additional 10-30 mg ketamine boluses administered every 10-15 minutes as needed, not to exceed a maximum dose of 2 mg/kg.

25-50 mcg of intravenous fentanyl will be administered every 10-15 minutes as needed during the procedure.

DRUGMidazolam

Midazolam will be administered as follows: an initial intravenous bolus of 1-2 mg midazolam followed by maintenance boluses of 0.5-1 mg intravenous midazolam as needed to achieve deep sedation.

Sponsors

CAMC Health System
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

This is a prospective, single-arm, open-label feasibility study designed to evaluate the safety and clinical utility of using a ketamine-based sedation regimen in place of general anesthesia in patients undergoing IR procedures that typically receive general anesthesia. All enrolled participants will receive the intervention according to a standardized protocol to determine if the approach can successfully facilitate adequate sedation without the need for anesthesiology support. The primary objective is to characterize the procedural success rate, with secondary objectives focusing on safety, patient-reported outcomes, and recovery metrics. This pilot study aims to provide the necessary preliminary data to support larger-scale, comparative investigations.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 18 and older * Planned to undergo an image-guided IR procedure for which general anesthesia would ordinarily be requested, as determined by the performing IR physician * Determined by the performing IR physician to be an appropriate candidate for attempted IR-led ketamine- based deep sedation, with anesthesiology available for escalation if needed * Ability to provide written informed consent for participation in a study involving deep sedation

Exclusion criteria

* Ingestion of solid food within 6-8 hours prior to the procedure, per institutional deep sedation guidelines * Known allergy or hypersensitivity to ketamine, fentanyl or midazolam * Inability to provide informed consent or lack of decision-making capacity * Prisoner status * Uncontrolled hypertension or other condition in which ketamine-associated sympathetic stimulation would pose unacceptable risk (e.g., aortic dissection, acute myocardial infarction) * Pregnancy or lactation, due to contraindication to ketamine/midazolam * History of schizophrenia or other psychotic disorders for which ketamine is contraindicated * Medical conditions that, in the judgment of the performing IR physician in consultation with anesthesiology, preclude safe administration of ketamine-based deep sedation

Design outcomes

Primary

MeasureTime frameDescription
Aim 1 - FeasibilityFrom enrollment in the study immediately before the procedure to the completion of the patient satisfaction survey given after surgical recovery, within 2-hours post-op. Enrollment, procedure, and survey are completed in the same day.For Aim 1, feasibility will be assessed by calculating the proportion of procedures completed without failure, where failure is defined as procedure abortion due to inadequate sedation or patient intolerance, or escalation to anesthesiology takeover and/or conversion to general anesthesia. The observed failure proportion will be reported with exact (Clopper-Pearson) 95% confidence intervals. Feasibility will be interpreted relative to the prespecified threshold of ≤10% failure.

Secondary

MeasureTime frameDescription
Patient-Reported PainPre-procedure (baseline; immediately before procedure) and post-procedure (immediately after recovery period; within 2 hours post-op).Pain will be assessed using the validated 10-point Numeric Rating Scale (NRS), where 0 represents no pain and 10 represents worst imaginable pain. The study coordinator will document pre-procedure pain and post-procedure pain in the immediate recovery period. If a participant reports no recall of the procedure, this will be recorded as "no recall of pain/procedure" rather than imputing a numeric score. All pain scale measurements occur the same day as the procedure, and there are no other longitudinal measurements.
Patient SatisfactionQuestionnaire given after recovery from procedure (within 2 hours post-op).Patient satisfaction will be assessed using a modified Heidelberg peri-anesthetic questionnaire (18 questions) administered in the recovery area prior to discharge or return to the inpatient unit. Questions 1-16 are rated on a scale from 1 (Strongly Disagree) to 4 (Strongly Agree). Question 17 asks if the patient would, in the future, have "more sedation," "same sedation," or "less sedation." Question 18 asks the patient to rate their level of pain on a scale from 0 (no pain) to 10 (worst possible pain).
Recovery DurationImmediately post-procedure to discharge from recovery area (within 2 hours post-op).Recovery duration will be defined as the time from procedure completion to discharge from the procedural recovery area or return to the inpatient unit, reflecting clinically meaningful recovery rather than anesthetic emergence alone.
Sedation-Related Adverse EventsThe procedure begins and finishes in one day. Adverse events that occur during the procedure, immediately after, and after recovery (within 2-hours post-procedure) will be recorded.Sedation-related adverse events will be prospectively documented and will include: * Hypotension or hypertension requiring intervention * Oxygen desaturation \<90% * Need for airway intervention * Escalation to anesthesiology takeover and/or conversion to general anesthesia * Administration of reversal agents * Post-procedural nausea, vomiting, or hallucinations not responsive to medications Procedure-related adverse events will include bleeding, pneumothorax, infection, and other complications classified according to Society of Interventional Radiology (SIR) Standards of Practice. Vital signs, including lowest oxygen saturation and lowest and highest blood pressure during the procedure, will be recorded. This outcome is for the single day in which the procedure occurs. No pre-procedural or longitudinal data is applicable.

Countries

United States

Contacts

CONTACTAmy R Deipolyi, M.D., Ph.D.
Amy.Deipolyi@vandaliahealth.org304-388-8199
CONTACTAdam M Belcher, Ph.D.
adam.belcher@vandaliahealth.org304-388-9920
PRINCIPAL_INVESTIGATORAmy R Deipolyi, M.D., Ph.D.

CAMC Department of Interventional Radiology

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026